{
  "id": 1500440,
  "title": "Roundup: Removing Impurities from Biomanufacturing",
  "url": "https://urgent.news/2026/08/17/roundup-removing-impurities-from-biomanufacturing",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-17T14:49:54.000Z",
  "source": {
    "name": "GEN Biotechnology",
    "slug": "gen-biotechnology",
    "url": "https://www.genengnews.com/topics/bioprocessing/roundup-removing-impurities-from-biomanufacturing/"
  },
  "original_language": "en",
  "account": "Impurity control is a fundamental aspect of biomanufacturing, directly impacting process, cell line, and formulation stability. Residual impurities can lead to oxidation, enzymatic degradation, protein unfolding, and aggregation, all of which threaten biotherapeutic potency and shelf life. To ensure product quality and patient safety, biomanufacturing leaders employ various technologies at different stages of processing.\n\nAgilent Technologies uses Agilent Bio-inert LC platforms in upstream and downstream workflows to remove process-related impurities like host cell proteins (HCPs), DNA, and media components. High-resolution multidimensional separations help identify complex mixtures and minimize the risk of co-eluting impurities. By employing these advanced analytical approaches, Agilent Technologies can maintain the integrity of biologics and metal-sensitive analytes.\n\nDownstream purification strategies have evolved to be more modality-specific. For peptide purification, LC solutions paired with integrated software workflows facilitate efficient yield and purity balance. Oligonucleotides often require orthogonal ion-pairing reverse phase (IP-RP) and anion exchange (AEX) chromatography to resolve sequence failures and closely related variants.\n\nLonza emphasizes the importance of orthogonal diversity combined with capacity redundancy and holistic process stewardship. Integrated Biologics Bioinformatics helps identify potential liabilities before any pipetting takes place. Primary harvest depth filtration and charged media media are critical in preventing host cell protein (HCP) accumulation. Downstream processing should leverage specialized affinity resins, enhanced washes, and reduced proteases to ensure product purity, especially when dealing with viral inactivation and impurity removal.\n\nMilliporeSigma focuses on advanced analytics, targeted purification technologies, and engineered impurity control across upstream processes. By minimizing impurity introduction through stringent raw material qualification and high-sensitivity analytical platforms like ICP-MS, MilliporeSigma can precisely characterize and specify low-level metal impurities. Engineered cell culture media further reduce variability at the source, and in-process controls and real-time monitoring ensure consistency throughout bioreactor operations. This integrated approach safeguards product quality, process consistency, and patient safety while reinforcing MilliporeSigma's leadership in differentiated bioprocessing solutions.",
  "summary": "GEN asked leaders in biomanufacturing: What technologies do you use to carry out effective impurity removal at specific points throughout upstream and downstream processing to ensure product quality and patient safety? The post Roundup: Removing Impurities from Biomanufacturing appeared first on GEN - Genetic Engineering and Biotechnology News .",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}